TOGETHER WE ARE BREAKING DOWN BARRIERS TO IMPROVE ACCESS TO THERAPIES FOR CANADIANS AFFECTED BY FSHD

Canadians affected by facioscapulohumeral muscular dystrophy (FSHD) could face substantial delays in accessing clinical trials and any Health Canada approved life-changing treatments and therapies when they become available. Muscular Dystrophy Canada (MDC) is working with the Canadian Neuromuscular Disease Registry (CNDR) and the Neuromuscular Disease Network for Canada (NMD4C) to help prevent that from happening.

“Studies show that Canadians have less frequent and timely access to therapies for rare diseases, like FSHD; that very few therapies approved elsewhere in the world are even submitted to Health Canada for regulatory approval; and, that if treatment is approved there is a vast difference in who has access across the provinces and we are working hard to change this,” said Stacey Lintern, CEO, Muscular Dystrophy Canada.

There are more than a dozen FSHD therapies currently in development. The work that MDC is leading will help introduce a patient registry and collect information to build a Canada-wide core dataset for FSHD to speed up development, approval and access to treatments regardless of where a person lives in Canada.

“We know from our experience with spinal muscular atrophy therapies that our government requires Canadian data when reviewing a treatment. With this FSHD dataset and registry, MDC wants to get out ahead of the treatments being developed and address the challenges and barriers to access so that Canadians can access treatments as soon as possible. We’re also hopeful more biopharmaceutical companies will establish sites, and conduct clinical trials in Canada,” added Lintern.

“The CNDR is dedicated to working in close partnership with Muscular Dystrophy Canada and NMD4C to promote opportunities to participate in cutting-edge clinical trials for patients affected by FSHD but to also collect data towards ensuring access to future therapies once approved,” said Dr Lawrence Korngut, National Principal Investigator and neurologist at the University of Calgary.

“Enabling Canadians living with FSHD to register in a single national system allows them to signal their interest in participating in clinical trials, provide the essential Canadian baseline data that the regulators want to see, and be contacted when new treatments become available,” said Dr Hanns Lochmüller, NMD4C Investigator and FSHD clinical trialist.

By engaging partners, MDC is committed to breaking down barriers that prevent Canadians from accessing life-changing treatments, not just for FSHD, but for all neuromuscular disorders and investigating additional opportunities that would benefit our community.

Would you like to help determine what is included in the FSHD dataset and share your Canadian experience? Join us for a virtual roundtable by emailing research@muscle.ca

RAISING THE BAR FOR NEUROMUSCULAR DISORDER RESEARCH AND CLINICAL CARE IN CANADA

Thanks to Muscular Dystrophy Canada’s (MDC) incredible supporters, when opportunities arise to improve the care, research and treatment of neuromuscular disorders (NMD) for Canadians, we’re able to act. Such was the case with the Neuromuscular Disease Network for Canada (NMD4C).

Launched in January 2020, with funding from MDC and the Canadian Institutes of Health Research (CIHR), NMD4C was created to provide a comprehensive, inclusive, open and enduring network through which Canadian stakeholders can share expertise and data, and collaborate on joint activities and research. In addition to helping fund the network, MDC also became an equal partner and helps support knowledge translation.

Three years later, MDC has worked with NMD4C to:

  • introduce support for clinical and post-doctoral research fellows;
  • provide up-to-date clinical and research education through monthly accredited webinars, and forums for dialogue and exchange;
  • create a national competency standard that recognizes advanced neuromuscular training;
  • develop an accredited and standardized Canadian neuromuscular fellowship curriculum;
  • build a virtual Canadian neuromuscular disorder biobank catalogue;
  • update the Canadian Neuromuscular Disease Registry by adding two new disease datasets;
  • establish NMD clinical trials, as well as clinical trial capacity;
  • and, launch ‘imPORTND’, the first patient-oriented training platform developed specifically for neuromuscular disease research.

“Being a patient partner enables me to have meaningful input into research, to increase its relevance to quality of life and ensure that among its measures are things that are important to patients,” said Corinne Kagan, Patient Research Partner and co-developer of the imPORTND training modules.

“As a partner and funder, MDC has ensured that Canadians affected by neuromuscular disorders remain at the forefront of NMD4C’s decision making, activities and outcomes. From investing in early career researchers and clinicians and developing a virtual biobank, to strengthening the clinical landscape, the goal has always been to positively influence the NMD healthcare experience in Canada and to build research capacity and knowledge about these rare disorders,” said Dr Homira Osman, Vice President of Research and Public Policy, Muscular Dystrophy Canada. “We (MDC) remain committed to the network, and to working together to raise the bar for clinical and research standards in Canada and build upon the momentum currently taking place in research.”

Learn more about imPORTND

To learn more about NMD4C and how you can support or become involved, contact research@muscle.ca

MDC IS HERE FOR YOU!

Whether you live on the east coast, the west coast, the Prairies or central Canada, MDC is here to support you. We have Service Specialists across the country who will be happy to work alongside you, ensuring you have the information and support you need. Meet Ryanne, our Service Specialist in Atlantic Canada.

“As a Service Specialist I am able to work directly with clients and their families to support them in achieving a wide range of goals and navigation of the healthcare system. When we are able to provide funding towards an essential piece of equipment, we are not only supporting our clients with the financial strain that accompanies living with a neuromuscular disorder, but we are also providing hope for the possibilities of what they will accomplish with this equipment. Being able to provide this kind of support and making positive connections with our families truly is my favorite part about working at MDC.”

“The majority of the disorders we cover are so rare that it can make you feel isolated. It is so important for our clients to understand that is why MDC is here, to ensure you do not have to navigate living with a neuromuscular disorder alone.”

Are you or someone you know living with a neuromuscular disorder? MDC has a wide range of programs and services designed to meet you where you are. Whether it is information on your disorder, helping you with accommodation needs at work or school, navigating the healthcare system, housing or financial issues, or helping you secure equipment – we’re here to help. Visit muscle.ca/services-support/need-help/ to find a Service Specialist near you, or call us at 1-800-567-2873.

TEN DOWN, THREE TO GO

Manitoba and Quebec latest provinces to embark on newborn screening for SMA

It’s been one year since we started working on making newborn screening (NBS) for spinal muscular atrophy (SMA) a reality for all Canadian babies. Thanks to a partnership with Novartis Canada and your unwavering support – there are only two provinces and a territory left to commit to this life-changing test. This spring, Quebec started planning for newborn screening for SMA, and Manitoba announced it moved from the planning phase to officially screening all babies.

Learn more “TEN DOWN, THREE TO GO”

RESEARCH FUNDING IS CHANGING NEUROMUSCULAR LANDSCAPE IN CANADA

Because of generous supporters, like you, nine new clinical and translational science research projects received funding this year. These projects are excellent examples of the high quality, exciting research taking place right here in Canada! We wouldn’t be able to support research like this without YOU.

2021-2022
RECIPIENTS:

Building a screenable human 3D neuromuscular junction model for neuromuscular disorders
Dr. Thomas Durcan
The Royal Institution for the Advancement of Learning/McGill University

Mitochondrial-targeted therapies to improve Duchenne muscular dystrophy outcomes
Dr. Christopher Perry
York University

Genome-wide DNA methylation profile in Duchenne muscular dystrophy
Dr. Craig Campbell
London Health Sciences Centre
(Lawson Health Research Institute)

Measuring balance in chronic inflammatory demyelinating polyneuropathy
Dr. Michael Berger
University of British Columbia

Endurance training as a novel therapeutic strategy for myotonic dystrophy type 1
Dr. Bernard Jasmin
University of Ottawa

QP-OPMD: Quantitative MRI imaging to assess progression in oculopharyngeal muscular dystrophy
Dr. Jodi Warman Chardon
Ottawa Hospital Research Institute

Exploring the impact of spinal bulbar muscular atrophy on persons self-identifying as Indigenous
Dr. Kerri Schellenberg
The University of Saskatchewan

The transition of TEENagers with spinal muscular atrophy to a multi-disciplinary adult program
Dr. Reshma Amin
The Hospital for Sick Children

Motor network connectivity in spinal muscular atrophy: new pathways for intervention
Dr. Maryam Oskoui
The Research Institute of the McGill University Health Centre

Learn more “RESEARCH FUNDING IS CHANGING NEUROMUSCULAR LANDSCAPE IN CANADA”

YOU’RE HELPING MAKE CLASSROOMS A SAFE AND ACCEPTING PLACE FOR ALL

Imagine being the only child in your class who has a neuromuscular disorder. Imagine being the only one who even knows what a neuromuscular disorder (NMD) is.

During a time when being understood, included and involved is critical, classroom environments can be a daunting place for anyone affected by an NMD. Muscular Dystrophy Canada’s AccessAbility program, graciously funded by donors like you, and the Canada Post Community Foundation, is working to change that for students.

Muscular Dystrophy Canada’s (MDC)Service Specialists work with students to develop an accessibility presentation focusing on their unique needs and abilities. This empowers the student to share their abilities with classmates and teachers, provide information to educators so they can expand their knowledge on enhancing accessibility and inclusion in schools, and decrease the negative stigma associated with disabilities.

Learn more “YOU’RE HELPING MAKE CLASSROOMS A SAFE AND ACCEPTING PLACE FOR ALL”

Additions to the Equipment Program Funding!

Additions to the Equipment Program Funding!

Because of donors, like you, MDC has added a substantial list of Assistive Technology to its Equipment funding list.

Assistive technology helps people affected by neuromuscular disorders (NMDs) to improve their health, safety, independence, and t increase their participation in education, the workforce and their community. These devices include; smart watch or wearables for fall detection and medical alert, communication devices, Robotic arm or eating device, Smart door locks and medication dispensers to name a few!

Learn more “Additions to the Equipment Program Funding!”

THE BOOTS ARE BACK AND WE NEED YOUR HELP!

No one has missed seeing Fire Fighters out in the community supporting individuals affected by neuromuscular disorders more than Fire Fighters themselves.

“We are so happy to be in a position where we can bring the boots back out into the community to raise funds and awareness.”

Dan Hamel, Chair of the National Fire Fighter Relations Committee

Learn more “THE BOOTS ARE BACK AND WE NEED YOUR HELP!”